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problem. The purpose of this study la to evaluate prospectively the accuracy 
of helteel computed tomegraphy ongiogmphy in (HCTA) in acute pulmonary 
embolism (PE). 
Methods: 119 patients (59 :t= 15 yearn) with clinically suspected acute 
pulmonary embolism (PE) wore enrolled in this study. All patients underwent 
both HCTA (5 ram.collimation, ?.5.minis table speed. 2.7-ram effective slice 
thickness, 120-150 mt of contmt;t materiel at 4 ml/e rote) end digital selective 
pulmonary angiogmphy (DSA) within 12 hour~ of each other. All examinations 
were analyzed In consensus by two observem who were unaware of the 
findings in the reference otudy (DSA), 
Results: HCTA wee tochnlcally succeseful in 115/t 19 (96%) eaaee. BSA 
shewed PE in 41 patlent~ (34%)', ~9 in central veaeels (95,1%) nnd P in sub- 
segmental vessels (4,0%), The HCTA findings (~errataled well with DSA with 
two f~loe.positlve and one false.negative results, The prospective sensitivity 
of HCTA wee 95%, the specificity wan 98%, the positive predictive value were 
97% and the negative prodl0tlvo ~alue wee 97%, Both one false.positive and 
ono false.negative results were in sub~egmental level, One tree.negative 
mault had acute aortic hematoma detected by HCTA, 
Conoluslen: HCTA can accurately depict PE, Detection of aubsegmental 
clots remains a limitation of HCTA. oven if thin.alice thickness as ~,7 mm 
was used, 
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~ Prevention of Pulmonary Embolism by Inferior Vena 
Cave Filter In Patlente With Proximal Deed Vein 
Thrombosis 
FI, Faivm, For PREf~IC Inv~,~tt~nt, Char ~ in f  Vincent, f]e..~n~on, France 
B~IC'~IN/- Vane Cave Fillers (VCF) am increasingly used for the procreation 
of pulmonary embollt;m (PE), However, the beneflt/risk ratio el VCF has novor 
been aeseseed, 
MethoaL~: PREPIC was a mutticentor randemlsod chmcat eal ~n presumed 
high rt~;k paliente with proximal Deep Vein Thembosis (DVT) allocated to VCF 
or without (control, C), In addition, all patlonts received Hopafins followed 
by oral anticoagulant ot el least 3 months in both groups. Lung scans: 
(~ pulmonary angtograms) were performed at Day I and Day 10. Now 
asymptomatic or symptomatic PE at Day 10 was the pnmaP/ endpomt 
Symptomatic PE, ~oc, urront DVT and Drouth wore blindly evaluated for two 
yearn, 
Results: 400 patients worn included (200 VCF. 200 C). The moan ago 
was 72 years, 49% of patients had an initial PE and 90% hod at least one 
presumed risk factor of PE, At Day 10, PE rate was significantly lower in VCF 
group (1,1% vs 4.8% =n C, p = 0.03). At 2 years, PE was not stgnilicantly 
dllforent between VCF end C (3.4% vs 6.3%, p = 0.16): mecurront DVT was 
morn frequent in VCF group (20.8% vs 11.6%, p = 0.02): death rate was high 
tn both groups (21.6% vs 20.1%, NS). 
Conclusion: PREPIC Teal demonstrates the immediate fficacy o1 filter 
for pmeventlon of PE. However, because of the obson/ed excess of recurrent 
DVT and the absence of benefit on mortality in patients receiving filter, the 
systematic use of this device cs not to be recommended in this population. 
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~ 7  Recombinant Hlrudln In the Treatment of Heperln 
Induced Thromboeytopenla (HIT) Type II 
U, Janssons, A. Gmeinachor ~, P, Hanmth Universi~, Hospita! of Aachen. 
Germany; ~ Insitute for Immunolooy ancl Transfusion Mechcine. 
Emst.Montz-Amdt.Uni~rsi~, Gmi~u'nld. Germany 
HIT type It is a lifo-thmeatoning side-effect of hepadn therapy which is associ- 
ated with severn arterial and venous thromboembolic complications (TEC). 
Although affected patients require sustained pamentoral nticoagulation the 
mere suspicion of HIT type II mandates immediate cessation of hoparin ther- 
apy. Recombinant hirudln [rH] (Rofludan ~ , Hoechst, Germany) has recently 
been approved for treatment of HIT in Germany. 
Methods: All patients at our institution with clinical criteria of HIT and labo- 
ratory confirmation of heparin-induced antibodies were included in the study. 
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Hoperln we8 discontinued end replaced by rH according to a multi-center- 
study-protocol. RH wet; monitored by aPTT with a target range of 1.5-3,0 
fold prolongation of oPTT values at baseline. 
Results: 29 patients (59+ yearn, 19 main) were studied from 12/94 to 1/97, 
19 patients (05%) had TEC, Pletelet nadir under hepann therapy wse 60 :t- 
39 GIgWL, Significant sustained recovery of ptatelet values woe observed 
rapidly after start of rH, APTT values were wilhln forger values. Duration of 
rH treatment was 13 ~= 9 daye. no new TEC o~errad, 3 Patients died. noa~ 
of the deaths wee misted 1o rH. 
Conclrt~ion: Treatment of patients ~qffefing from HIT typ~ II wlth dd le~ing 
to rapid and sustained increase o1 plalelet ~'ounta while providing eun¢'~ent 
antleoagulstien, rH is t~ aafa and elfe¢tive alternative ant~-oagu!ant d~;I in 
patients with HIT type II, 
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~ l s  It Safe to Withhold or  Reveme Waffer!n ThemlW In 
Patients With Proethet!¢ Heart Va lwe After n ~ jor  
81~? 
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The ask of thmmboembehsm when Wadann therapy is withhold Or ~velSed 
following a molar bleed in pmsthefio vahm patients is unknown. We identified 
29 patients (pts) with prosthetic head valves hosl)ilel[~l for a major bleed 
between 1990-1997, The aveffige age was 61 years with 16 males and 13 
females, 24 pts had St Jude valves, 4 had btoprosthehc valves and 2 each 
with ball Cage and tilting disc valves. V~htos were located in the mdrat posmon 
in 12 pts, aortic; tn 12, both mitml and aortK: in 4 and mcuspid in one. The 
average interval from valve surge W to the index bleed was 7 yearn. 26 pts 
had a gastrointestinal orretroperitoneat bleed, 2 had intrac~mal hemonhage 
and 1 had a subdurat hematoma. Average International Noemaltzed robe was 
3,3. Vitamin K was given to 5 and plasma to 7 to reverse antcoagulatton. 
Surgical intervention was required in 9 pts to treat bleeding, 4 o! ~t~,~m 
died in hospital. An additional 4 patients were lost to to;lewup. Average 
duration off anticeagutation was 15 days. ranging from 1 to 90. No pabent 
hod a clinically recognized thmmboembohc event while off anttcoagutat,on 
and them were no throraboembolic events in patients whose ant~Kjulahon 
was revemed. 23 patients had their wadann therapy resumed at the hma o| 
discharge. At 6 month tollowup. 10 patients had sustained recurrent bleeds. 
all gestmintsstinal, and one additional patient died. 
Conclusions: 1. Thromboembolic r~sk is low in patients with prosthetic 
heart valves and a major bleed when their anticoagulat~n is wtthhek:l or 
meversed. 2. Recurrent bleeding within 6 months o! resumption o! ant¢oag- 
ulation is common, 3. Although further study is warranted it appears that 
the ask of recunent bleeding after resumption of wartann may ouhvetgh the 
ask el thmemboembolism if wartann =s withheld in some patients ea~. after 
mesolution el major bleeding. 
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~ Differences Between Cardiologists and Generalists 
In Isehemlc Heart Disease Expenditures for 
Medicare Managed Care 
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Background." CapiV, tion paid to a pnncipal provider is becoming a more 
common method el payment under managed came. How elderly patients with 
ischomic heart disease (IHD) differ in cost under cardiologist (C) or generalist 
(G) care is unknown. 
Methods: We examined 1992 Medicare expenditures of 250,514 patients 
with IHD (ICD-9 codes 410-414). We defined pnncipal provider as the spe- 
cialty with the most Part B outpatient claims: 62% wore in the G (general 
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